Literature DB >> 9007594

Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans.

A Buxbaum1, A Georgopoulos.   

Abstract

A persistent suppression of bacterial growth following limited exposure to an antimicrobial agent, the postantibiotic effect (PAE), has been described for a variety of antibiotics and microorganisms. In this study the PAE of ceftriaxone and gentamicin was determined in vitro on three strains each of Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans. The strains were exposed to the substances for 2 h at varying concentrations. Ceftriaxone was used at the minimal inhibitory concentration (MIC) and 1/2 MIC and gentamicin at 1/2 MIC, 1/4 MIC, and 1/8 MIC, each alone and in combination. Antibiotic concentrations were reduced by 1,000-fold dilution, bacterial regrowth was consequently monitored by viable count. The PAE of ceftriaxone alone reached up to 145 min (MIC) and 50 min (1/2 MIC), that of gentamicin alone up to 170 min (1/2 MIC), 135 min (1/4 MIC) and 70 min (1/8 MIC), depending on the bacterial species. Combinations of the antibiotics produced longer PAEs than one substance alone; the longest PAE was produced by the combination of ceftriaxone (MIC) and gentamicin (1/2 MIC) lasting up to 320 min (S. viridans). It may be important to take the PAE into account when evaluating dosing intervals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9007594     DOI: 10.1007/bf01713048

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  32 in total

1.  Once daily dosing of aminoglycoside: one step forward.

Authors:  J C Pechère; W A Craig; F Meunier
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

2.  The bactericidal action of penicillin in vivo: the participation of the host, and the slow recovery of the surviving organisms.

Authors:  H EAGLE; R FLEISCHMAN; A D MUSSELMAN
Journal:  Ann Intern Med       Date:  1950-09       Impact factor: 25.391

3.  Postantibiotic effect of penicillin plus gentamicin versus Enterococcus faecalis in vitro and in vivo.

Authors:  M T Hessen; P G Pitsakis; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

4.  Clinical and laboratory evidence for inactivation of gentamicin by carbenicillin.

Authors:  J E McLaughlin; D S Reeves
Journal:  Lancet       Date:  1971-02-06       Impact factor: 79.321

5.  Growth kinetics of respiratory pathogens after short exposures to ampicillin and erythromycin in vitro.

Authors:  A U Gerber; W A Craig
Journal:  J Antimicrob Chemother       Date:  1981-11       Impact factor: 5.790

6.  Postantibiotic suppression of bacterial growth.

Authors:  R W Bundtzen; A U Gerber; D L Cohn; W A Craig
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

7.  Antimicrobial therapy of experimental enterococcal endocarditis.

Authors:  E W Hook; R B Roberts; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

8.  Carbenicillin inactivation of aminoglycosides in patients with severe renal failure.

Authors:  R Weibert; W Keane; F Shapiro
Journal:  Trans Am Soc Artif Intern Organs       Date:  1976

9.  Penicillin-aminoglycoside synergy and post-antibiotic effect for enterococci.

Authors:  T G Winstanley; J G Hastings
Journal:  J Antimicrob Chemother       Date:  1989-02       Impact factor: 5.790

10.  Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.

Authors:  D E Johnson; B Thompson; F M Calia
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

View more
  1 in total

1.  Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia.

Authors:  R J Tomlinson; M Ronghe; C Goodbourne; C Price; J S Lilleyman; S Das; V Saha
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.